Nymox Pharmaceutical Late- Stage Clinical Trials Substantiating Investor Interest; Analyst Report by BrokerBank Securities, Inc. - NBC12.com - Richmond, VA News

Nymox Pharmaceutical Late- Stage Clinical Trials Substantiating Investor Interest; Analyst Report by BrokerBank Securities, Inc.

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE BrokerBank Securities, Inc.

NEW YORK, May 14, 2014 /PRNewswire/ -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company has just completed its second Phase 3 clinical trial for its new drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for other indications such as E. coli infection, Alzheimer's disease, oncology, and infectious disease.

BPH (enlarged prostate) is one of the most commonly diagnosed diseases in the male U.S. population. The condition can seriously impact the health and quality of life of older men and can lead to acute urinary retention, incontinence, and other serious consequences. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and from 26 to 46% of men between the ages of 40 to 79 years suffer from moderate to severe urinary problems and symptoms associated with BPH.

The Company also currently markets  NicAlert® and TobacAlert® tests for measuring tobacco product exposure and AlzheimAlert®, a test to aid in the diagnosis of Alzheimer's disease.

A full report on NYMX that includes risk factors, industry review, financial position, potential revenues, and review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link:

http://bit.ly/NYMX-AnalystReport

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

COMPLIANCE PROCEDURE   

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Mark Bonacci, Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

A full disclaimer can be found by viewing the full analyst report.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@smallcapir.com. For any urgent concerns or inquiries please contact us at admin@smallcapir.com.   

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow